
|Articles|July 1, 2001
- Pharmaceutical Executive-07-01-2001
- Volume 0
- Issue 0
Submerged
Author(s)Wayne Koberstein
Is the pharmaceutical industry surrounded by its critics? Can the industry be liberated from the moral bind others want to impose on it? Those are questions I asked and attempted to answer in two recent editorials (PE April and June 2001). Actually, the simple answer was yes to both. But other answers prove more complex.
Advertisement
Articles in this issue
about 25 years ago
Pharmacies: OTC Price Warsabout 25 years ago
One Disease at a Timeabout 25 years ago
Overview of the Industry: A World of Opportunitiesabout 25 years ago
The Power Shiftabout 25 years ago
A Giant Stumblesabout 25 years ago
Overruled: No More Dual Pricingabout 25 years ago
Generic ThreatAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Significance of FDA’s First Warning Letter for Inappropriate Use of AI
2
Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion
3
Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance
4
M&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo
5




